



Walter Mingrone

Kontakt

Walter Mingrone

Publikationen (18)

Fischer S, Gillessen S, Stalder O, Terbuch A, Cathomas R, Schmid F, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Alex Kluth L, Seifert B, Templeton A, Mingrone W, Ufe M, Fischer N, Beyer J, Woelky R, Omlin A, Vogl U, Hoppe K, Kamradt J, Rothschild S, Rothermundt C. First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). *Eur Urol Open Sci* 2024; 68:68-74.

Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Seifert B, Alex Kluth L, Ufe M, Mingrone W, Templeton A, Fischer N, Rothschild S, Woelky R, Gillessen S, Cathomas R. The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. *Eur Urol Open Sci* 2023; 50:57-60.

Hitz F, Lang N, Mey U, Mingrone W, Moccia A, Taverna C, Novak U, Stenner F, Schmidt A, Mamot C, Fischer N, Putora P. Decision-making among experts in advanced Hodgkin Lymphoma. *Oncology* 2022

Pratsinis M, Fankhauser C, Pratsinis K, Beyer J, Bühler E, Cathomas R, Fischer N, Hermanns T, Hirschi-Blickenstorfer A, Kamradt J, Alex Kluth L, Zihler D, Mingrone W, Müller B, Nestler T, Rothschild S, Seifert B, Templeton A, Terbuch A, Ufen M, Woelky R, Gillessen S, Rothermundt C. Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. *Eur Urol Open Sci* 2022; 40:16-18.

Moccia A, Rauch D, Vorobiof D, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Raats J, Del Giglio A, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Zucca E. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. *Blood Adv* 2020; 4:5951-5957.

Rueff J, Weixler B, Viehl C, Ochsner A, Warschkow R, Gueller U, Mingrone W, Zuber M. Improved quality of colon cancer surveillance after implementation of a personalized surveillance schedule. *J Surg Oncol* 2020

Hench I, Vlajnic T, Bubendorf L, Burg P, Tolnay M, Ruiz C, Rothermundt C, Püschel H, Mestre R, Mingrone W, Kremer E, Hermanns T, Hench J, Gillessen Sommer S, Fischer N, Costa L, Cathomas R, Sakk S. Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial). *Cancers (Basel)* 2019; 11

Zucca E, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei S, Ghielmini M, Kimby E, Novak U, Lohri A, Ferreri A, Rondeau S, Vanazzi A, Østenstad B, Mey U, Rauch D, Wahlin B, Hitz F, Hernberg M, Johansson A, de Nully Brown P, Hagberg H, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. *Blood* 2019; 134:353-362.

Rothermundt C, Woelky R, Fankhauser C, Kunit T, Fischer N, Inauen R, Kamradt J, Ziegler K, Haynes A, Jüni P, Grassmugg T, Terbuch A, Thurneisen C, Cathomas R, Müller B, Mingrone W, Hirschi-Blickenstorfer A, Wehrhahn T, Ruf C, Rothschild S, Seifert B, Gillessen Sommer S. Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). *Swiss Med Wkly* 2018; 148:w14674.

Metaxas Y, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, O'Byrne K, Petrasch U, Wolleb S, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak A, Gautschi O, Bartnick T, Hughes B, Bouchaab H, Rothschild S, Pavlakis N, John T. Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. *J Thorac Oncol* 2018

Rothermundt C, Woelky R, Fankhauser C, Kunit T, Fischer N, Inauen R, Kamradt J, Ziegler K, Haynes A, Jüni P, Grassmugg T, Terbuch A, Thurneysen C, Cathomas R, Müller B, Mingrone W, Hirschi-Blickenstorfer A, Wehrhahn T, Ruf C, Rothschild S, Seifert B, Gillessen Sommer S. Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). *Swiss Med Wkly* 2018; 148:w14640.

Papazoglou D, Stenner F, Kühne R, Baumann S, Richner J, Schmid M, von Burg P, von Rohr L, Nussbaum C, Mingrone W, Barth A, Winterhalder R, Hasler L, Rothermundt C, Gillessen Sommer S, Cathomas R, Berthold D, Wannesson L, Rothschild S. Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program. *Clin Genitourin Cancer* 2016

Taverna C, Zucca E, Heijnen I, Rusterholz C, Rondeau S, Biaggi Rudolf C, Lohri A, Vorobiof D, Rauch D, Raats J, Laszlo D, Vanazzi A, Del Giglio A, Cevreska L, Pabst T, Mingrone W, Hitz F, Martinelli G, Ghielmini M. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. *J Clin Oncol* 2015; 34:495-500.

Renner C, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N, Bouabdallah K, Trojan A, Zinzani P, Gressin R, Klingbiel D, Dietrich P, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. *Haematologica* 2012; 97:1085-91.

Ruhstaller T, Brauchli P, Inauen R, Widmer L, Mingrone W, Gautschi O, Rauch D, Schneider P, Montemurro M, Moosmann P, von Moos R, Kranzbuehler H, Dietrich D, Pless M, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). *J Clin Oncol* 2011; 29:626-31.

Koeberle D, Herrmann R, Mora O, Ruhstaller T, Strasser F, Beretta K, Mingrone W, Caspar C, Dietrich D, Gerber D, Borner M, Saletti P, Swiss Group for Clinical Cancer Research. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26:3702-8.

Bernhard J, Pestalozzi B, Köhne C, Mingrone W, Stemmer S, Tamas K, Kornek G, Koeberle D, Herrmann R, Figer A, Bauer J, Saletti P, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26:3695-701.

Herrmann R, Stemmer S, Tamas K, Kornek G, Köberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W, Swiss Group for Clinical Cancer Research, Mingrone W, Köhne C, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2007; 25:2212-7.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch